The race to develop a medicine or cure to fight Covid19 was mainly focused on developing a vaccine, which would prevent one from getting severely sick or having severe symptoms of Covid19, leading to death.
Top research and pharmaceutical companies spent months of sleepless night and research to finally come out with a working vaccine against Covid19. The announcement of an effective vaccine brought some sigh of relief to the world, as we could finally return back to our normal lives, at least when the virus is very much under control.
Now a new promising drug from the manufacturing pharmaceutical company Merck, has been announced. "Molnupiravir" as it is called, was announced after a research found that Merck's experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus. A study which has generated several debate and controversy after it was released by the company.
When this is drug finally approved by the various regulatory authorities, it will be the first of its kind, an oral Covid19 pill, and most importantly, it could be obtained OTC ( Over the Counter) in the near future.
Until the last person is either vaccinated, immune or resistant to the Covid19 virus and all its variants, the battle against Covid19 has not ended.
In the meantime, pharmaceutical companies are hopping on to the new drug and will soon decide how pricing will be done and how many quantities will be produced, once approval has been given by the various regulatory bodies.
Content created and supplied by: MissChris (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More